CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

被引：20

作者：

Bao, Shunshun ^{[1
]}

Darvishi, Mohammad ^{[2
]}

Amin, Ali ^{[3
,4
]}

Al-Haideri, Maysoon T. ^{[5
]}

Patra, Indrajit ^{[6
]}

Kashikova, Khadisha ^{[7
]}

Ahmad, Irfan ^{[8
]}

Alsaikhan, Fahad ^{[9
]}

Al-qaim, Zahraa Haleem ^{[10
]}

Al-Gazally, Moaed E. ^{[11
]}

Kiasari, Bahman Abedi ^{[12
]}

Tavakoli-Far, Bahareh ^{[13
,14
]}

Sidikov, Akmal A. ^{[15
]}

Mustafa, Yasser Fakri ^{[16
]}

Akhavan-Sigari, Reza ^{[17
,18
]}

机构：

[1] Xuzhou Med Univ, Clin Med Coll 1, Xuzhou 221000, Peoples R China

[2] AJA Univ Med Sci, Infect Dis & Trop Med Res Ctr IDTMRC, Dept Aerosp & Subaquat Med, Tehran, Iran

[3] Umm Al Qura Univ, Deanship Sci Res, Mecca 21955, Saudi Arabia

[4] Mansoura Univ, Fac Sci, Zool Dept, Mansoura 35516, Egypt

[5] Cihan Univ Erbil, Dept Physiotherapy, Erbil, Kurdistan Regio, Iraq

[6] Natl Inst Technol Durgapur, Durgapur, W Bengal, India

[7] Kazakh Russian Natl Med Univ, Alma Ata, Kazakhstan

[8] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia

[9] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Alkharj, Saudi Arabia

[10] Al Mustaqbal Univ Coll, Dept Anesthesia Tech, Hillah, Iraq

[11] Univ Al Ameed, Coll Med, Karbala, Iraq

[12] Univ Tehran, Fac Vet Med, Virol Dept, Tehran, Iran

[13] Alborz Univ Med Sci, Dietary Supplements & Probiot Res Ctr, Karaj, Iran

[14] Alborz Univ Med Sci, Fac Med, Dept Physiol & Pharmacol, Karaj, Iran

[15] Ferghana Med Inst Publ Hlth, Rector, Ferghana, Uzbekistan

[16] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul 41001, Iraq

[17] Univ Med Ctr Tuebingen, Dept Neurosurg, Tubingen, Germany

[18] Coll Humanum Warsaw Management Univ, Dept Hlth Care Management & Clin Res, Warsaw, Poland

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 10期

关键词：

CXCR4; CXCL12; axis; blockers; Cancer; Immunotherapy; CELL-DERIVED FACTOR-1-ALPHA; TO-MESENCHYMAL TRANSITION; PREDICTS POOR-PROGNOSIS; TUMOR-GROWTH; IN-VITRO; HEPATOCELLULAR-CARCINOMA; ANTI-CXCR4; ANTIBODY; PROSTATE-CANCER; SIGNALING AXIS; HEMATOPOIETIC STEM;

D O I：

10.1007/s00432-022-04444-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.

引用

页码：7945 / 7968

页数：24

共 302 条

[1] The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression [J].

Abraham, M. ;

Klein, S. ;

Bulvik, B. ;

Wald, H. ;

Weiss, I. D. ;

Olam, D. ;

Weiss, L. ;

Beider, K. ;

Eizenberg, O. ;

Wald, O. ;

Galun, E. ;

Avigdor, A. ;

Benjamini, O. ;

Nagler, A. ;

Pereg, Y. ;

Tavor, S. ;

Peled, A. .

LEUKEMIA, 2017, 31 (11) :2336-2346

[2] Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-Benzoyl-TNI4003 [J].

Abraham, Michal ;

Biyder, Katia ;

Begin, Michal ;

Wald, Hanna ;

Weiss, Ido D. ;

Galun, Eithan ;

Nagler, Arnon ;

Peled, Amnon .

STEM CELLS, 2007, 25 (09) :2158-2166

[3] MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells [J].

Afshar-Khamseh, Reyhaneh ;

Javeri, Arash ;

Taha, Masoumeh Fakhr .

TISSUE & CELL, 2021, 73

[4] Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer [J].

Akashi, Takuya ;

Koizumi, Keiichi ;

Tsuneyama, Koichi ;

Saiki, Ikuo ;

Takano, Yasuo ;

Fuse, Hideki .

CANCER SCIENCE, 2008, 99 (03) :539-542

[5] Single nucleotide polymorphisms associated with gastric cancer in Iranian patients [J].

Alghasi, Arash ;

Farnoosh, Gholamreza ;

Boroujeni, Ali Saeedi ;

Bahadoram, Mohammad ;

Gandomkari, Sima Tahmaseby ;

Mahmoudian-Sani, Mohammad-Reza .

IMMUNOPATHOLOGIA PERSA, 2021, 7 (02)

[6] Relation between Immune cell response and stemness genes expression in breast cancer; A new approach in NANOG gene and Let7-a expression in breast cancer cell lines [J].

Aliyari-Serej, Zeynab ;

Ebrahimi, Ayyub ;

Kazemi, Tohid ;

Najafi, Souzan ;

Roshani, Elmira ;

Ebrahimi-Kalan, Mohammad ;

Baradaran, Behzad .

IMMUNOPATHOLOGIA PERSA, 2020, 6 (02)

[7] Antioxidant, antibacterial and anticancer efficacy of Alternaria chlamydospora-mediated gold nanoparticles [J].

Ameen, Fuad ;

Al-Maary, Khalid S. ;

Almansob, Abobakr ;

AlNadhari, Saleh .

APPLIED NANOSCIENCE, 2022, 13 (3) :2233-2240

[8]

Amri A., 2022, J PARATHYR DIS, V10, DOI [10.34172/jpd.2022.11162, DOI 10.34172/JPD.2022.11162]

[9] A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia [J].

Andritsos, Leslie A. ;

Byrd, John C. ;

Cheverton, Peter ;

Wu, Jingyang ;

Sivina, Mariela ;

Kipps, Thomas J. ;

Burger, Jan A. .

LEUKEMIA & LYMPHOMA, 2019, 60 (14) :3461-3469

[10]

Andtbacka R., 2018, RNA NORMALIZED COUNT, V400, P200

← 1 2 3 4 5 6 7 8 9 10 →